Hasil Pencarian - Daniel Gusenleitner

  • Menampilkan 1 - 6 hasil dari 6
Perbaiki Hasil
  1. 1
    Genomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of action.

    Genomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of action. oleh Daniel Gusenleitner, Scott S Auerbach, Tisha Melia, Harold F Gómez, David H Sherr, Stefano Monti

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

    Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients oleh Priyanka B. Subrahmanyam, Zhiwan Dong, Daniel Gusenleitner, Anita Giobbie-Hurder, Mariano Severgnini, Jun Zhou, Michael Manos, Lauren M. Eastman, Holden T. Maecker, F. Stephen Hodi

    Diterbitkan 2018-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)

    Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (C... oleh Dirk Schadendorf, Caroline Robert, Antoni Ribas, Reinhard Dummer, Paolo A Ascierto, Georgina V Long, Daniel Gusenleitner, Eduard Gasal, Hussein A Tawbi, Alexander Savchenko, Jan C Brase, Paul D Nathan, James Garrett, Keith T Flaherty, Güllü Görgün

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities

    Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities oleh Elizabeth A. Morgan, M. Patrick Sweeney, Tamiwe Tomoka, Nadja Kopp, Daniel Gusenleitner, Robert A. Redd, Christopher D. Carey, Leo Masamba, Steve Kamiza, Geraldine S. Pinkus, Donna S. Neuberg, Scott J. Rodig, Danny A. Milner, Jr, David M. Weinstock

    Diterbitkan 2016-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

    A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies oleh Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S. Hong, Lillian L. Siu, Miguel Martin, Michela Maur, Rina Hui, Ross A Soo, Joanne Chiu, Tian Zhang, Brigette Ma, Chrisann Kyi, Daniel SW Tan, Philippe A. Cassier, John Sarantopoulos, Andrew Weickhardt, Richard D. Carvajal, Jennifer Spratlin, Taito Esaki, Fréderic Rolland, Wallace Akerley, Barbara Deschler-Baier, Lawrence Rispoli, Tanay S. Samant, Niladri Roy Chowdhury, Daniel Gusenleitner, Eunice L. Kwak, Vasileios Askoxylakis, Filippo De Braud

    Diterbitkan 2024-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

    Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies oleh Tian Zhang, Filippo de Braud, Taito Esaki, Wallace Akerley, Chrisann Kyi, Richard D Carvajal, Daniel Gusenleitner, Patrick Schöffski, Miguel Martin, David S Hong, Amy Prawira, Jürgen Krauß, Nidhi Patel, Rina Hui, Andrew Weickhardt, Niladri Roy Chowdhury, Daniel S W Tan, María Ochoa-de-Olza, John Sarantopoulos, Ross A Soo, Michela Maur, Barbara Deschler-Baier, Allen Lau, Tanay S Samant, Tyler Longmire, Catherine A Sabatos-Peyton, Radha Ramesh, Tiancen Hu, Ana Carion, Padmaja Yerramilli-Rao, Vasileios Askoxylakis, Eunice L Kwak

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: